Moderna (MRNA) Cash from Operations (2018 - 2026)

Moderna (MRNA) has 9 years of Cash from Operations data on file, last reported at 630000000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations rose 39.25% year-over-year to 630000000.0 in Q1 2026; TTM through Mar 2026 was 1466000000.0, a 51.97% increase from a year earlier, with the FY2025 full-year figure at 1873000000.0, up 37.65% from the prior year.
• Cash from Operations for Q1 2026 stood at 630000000.0, down from 930000000.0 in the prior quarter.
• Over the last five years, Cash from Operations for MRNA reached as high as 2763000000.0 in Q1 2022 and fell as low as 1600000000.0 in Q3 2023.
• Historically, Cash from Operations has averaged 214352941.18 across 5 years, with a median of 847000000.0 in 2025.
• Across the five-year window, Cash from Operations slumped 734.92% in 2023 and soared 45.91% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 1662000000.0 in 2022, then sank by 62.58% to 622000000.0 in 2023, then soared by 32.64% to 825000000.0 in 2024, then climbed by 12.73% to 930000000.0 in 2025, then sank by 167.74% to 630000000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 630000000.0 in Q1 2026, 930000000.0 in Q4 2025, and 847000000.0 in Q3 2025.